Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 5: Patient Safety and Quality Assurance
5PSQ-068
THE HOSPITAL PHARMACIST'S INTERVENTIONS IN THE POST-MARKETING PHARMACOVIGILANCE OF ANTI-ASTHMATIC BIOLOGICS: A REAL LIFE ANALYSIS
5PSQ-067
DRUG UTILIZATION PROFILES OF ADVANCED THERAPY MEDICINAL PRODUCTS: A REAL WORLD EVIDENCE STUDY
5PSQ-066
SURVIVAL ANALYSIS OF REGORAFENIB IN PATIENTS WITH COLORECTAL CANCER. FIRST RESULTS OF REGORAFENIB USE IN REAL CLINICAL PRACTICE
5PSQ-065
INTESTINAL PERFORATION AFTER CRS AND ICANS IN A CAR-T TREATED PATIENT: A CLINICAL CASE REPORT.
5PSQ-064
ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON DIRECT ACTING ORAL ANTICOAGULANTS IN A TERTIARY CARE HOSPITAL.
5PSQ-063
ADJUVANTE ANALGESICS INTERACTIONS: HOW TO MANAGE PAIN IN PATIENTS RECEIVING ORAL THERAPY FOR BREAST CANCER TREATMENT
5PSQ-062
SAFETY EVALUATION OF PEMBROLIZUMAB IN MONOTHERAPY
5PSQ-061
CURRENT PRACTICE OF PEDIATRIC OFF-LABEL PRESCRIPTIONS IN A PEDIATRIC HOSPITAL
5PSQ-060
REAL-LIFE DATA ON THE EFFECTIVENESS AND SAFETY OF CABOTEGRAVIR/RILPIVIRINE IN A THIRD-LEVEL HOSPITAL
5PSQ-059
STUDY OF THE USE OF CEFTAZIDIME/AVIBACTAM IN A FIRST LEVEL HOSPITAL
5PSQ-058
EFFICACY EVALUATION OF ANTI-PCSK9 DRUGS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA.
5PSQ-057
ANTICHOLINERGIC BURDEN ASSESSMENT IN INSTITUTIONALIZED PATIENTS
5PSQ-056
VACCINATION COVERAGE AGAINST PENUMOCOCCUS FOR PEOPLE LIVING WITH HIV BEFORE AND AFTER THE COVI-19 PANDEMIC
5PSQ-055
EFFICACY AND SAFETY OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS TREATMENT
5PSQ-054
EVALUATION OF AN APPLICATION TO HELP FOR THE ADEQUACY OF THE DOSAGE OF ANTIBIOTICS IN RENAL FAILURE
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
Follow Us